<DOC>
	<DOCNO>NCT00055302</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy anastrozole 1 mg give daily subject McCune-Albright Syndrome .</brief_summary>
	<brief_title>Arimidex McCune Albright Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrous Dysplasia , Polyostotic</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>inform write consent parent/legal guardian subject assent ( need local requirement ) females less equal 10 year age diagnose McCuneAlbright Syndrome progressive precocious puberty Any one following regard criterion exclusion study : prior treatment MAS associate progressive precocious puberty third generation aromatase inhibitor ( anastrozole , letrozole , exemestane ) clinical response see concomitant treatment precocious puberty associate MAS , exception bisphosphonates polyostotic fibrous dysplasia LHRH analogues case central precocious puberty liver function test screen visit ( AST , ALT ) &gt; = 3x upper limit reference range age know hypersensitivity component study medication</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>vaginal bleeding</keyword>
	<keyword>advanced bone age</keyword>
	<keyword>fibrous dysplasia</keyword>
	<keyword>MAS</keyword>
	<keyword>McCune-Albright Syndrome</keyword>
</DOC>